Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
ABSTRACT Importance The use of factor VIII (FVIII) concentrates under pharmacokinetic (PK) guidance has become the main approach for treatment of hemophilia. However, limited PK research has been conducted in Chinese pediatric patients. Objective To investigate the PK parameters of various FVIII con...
Saved in:
Main Authors: | Zhenping Chen (Author), Kun Huang (Author), Gang Li (Author), Yingzi Zhen (Author), Xinyi Wu (Author), Ai Di (Author), Guoqing Liu (Author), Zekun Li (Author), Iorio Alfonso (Author), Runhui Wu (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
by: Guoqing Liu, et al.
Published: (2022) -
Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
by: Di Ai, et al.
Published: (2022) -
Low‐dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor‐titer below 200 BU/mL
by: Zhengping Li, et al.
Published: (2024) -
Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
by: Byung Suk Moon, et al.
Published: (2013) -
Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
by: Alanna McEneny-King, et al.
Published: (2017)